Joseph E Kiss1, Donald Brambilla2, Simone A Glynn3, Alan E Mast4, Bryan R Spencer5, Mars Stone6, Steven H Kleinman7, Ritchard G Cable8. 1. Institute for Transfusion Medicine, Pittsburgh, Pennsylvania. 2. RTI, Rockville, Maryland. 3. National Heart, Lung, and Blood Institute, Bethesda, Maryland. 4. BloodCenter of Wisconsin, Milwaukee. 5. American Red Cross, Dedham, Massachusetts. 6. Blood Systems Research Institute, San Francisco, California. 7. University of British Columbia, Victoria, Canada. 8. American Red Cross, Farmington, Connecticut.
Abstract
IMPORTANCE: Although blood donation is allowed every 8 weeks in the United States, recovery of hemoglobin to the currently accepted standard (12.5 g/dL) is frequently delayed, and some donors become anemic. OBJECTIVE: To determine the effect of oral iron supplementation on hemoglobin recovery time (days to recovery of 80% of hemoglobin removed) and recovery of iron stores in iron-depleted ("low ferritin," ≤26 ng/mL) and iron-replete ("higher ferritin," >26 ng/mL) blood donors. DESIGN, SETTING, AND PARTICIPANTS: Randomized, nonblinded clinical trial of blood donors stratified by ferritin level, sex, and age conducted in 4 regional blood centers in the United States in 2012. Included were 215 eligible participants aged 18 to 79 years who had not donated whole blood or red blood cells within 4 months. INTERVENTIONS: One tablet of ferrous gluconate (37.5 mg of elemental iron) daily or no iron for 24 weeks (168 days) after donating a unit of whole blood (500 mL). MAIN OUTCOMES AND MEASURES: Time to recovery of 80% of the postdonation decrease in hemoglobin and recovery of ferritin level to baseline as a measure of iron stores. RESULTS: The mean baseline hemoglobin levels were comparable in the iron and no-iron groups and declined from a mean (SD) of 13.4 (1.1) g/dL to 12.0 (1.2) g/dL after donation in the low-ferritin group and from 14.2 (1.1) g/dL to 12.9 (1.2) g/dL in the higher-ferritin group. Compared with participants who did not receive iron supplementation, those who received iron supplementation had shortened time to 80% hemoglobin recovery in both the low-ferritin (mean, 32 days, interquartile range [IQR], 30-34, vs 158 days, IQR, 126->168) and higher-ferritin groups (31 days, IQR, 29-33, vs 78 days, IQR, 66-95). Median time to recovery to baseline ferritin levels in the low-ferritin group taking iron was 21 days (IQR, 12-84). For participants not taking iron, recovery to baseline was longer than 168 days (IQR, 128->168). Median time to recovery to baseline in the higher-ferritin group taking iron was 107 days (IQR, 75-141), and for participants not taking iron, recovery to baseline was longer than 168 days (IQR, >168->168). Recovery of iron stores in all participants who received supplements took a median of 76 days (IQR, 20-126); for participants not taking iron, median recovery time was longer than 168 days (IQR, 147->168 days; P < .001). Without iron supplements, 67% of participants did not recover iron stores by 168 days. CONCLUSIONS AND RELEVANCE: Among blood donors with normal hemoglobin levels, low-dose iron supplementation, compared with no supplementation, reduced time to 80% recovery of the postdonation decrease in hemoglobin concentration in donors with low ferritin (≤26 ng/mL) or higher ferritin (>26 ng/mL). TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01555060.
RCT Entities:
IMPORTANCE: Although blood donation is allowed every 8 weeks in the United States, recovery of hemoglobin to the currently accepted standard (12.5 g/dL) is frequently delayed, and some donors become anemic. OBJECTIVE: To determine the effect of oral iron supplementation on hemoglobin recovery time (days to recovery of 80% of hemoglobin removed) and recovery of iron stores in iron-depleted ("low ferritin," ≤26 ng/mL) and iron-replete ("higher ferritin," >26 ng/mL) blood donors. DESIGN, SETTING, AND PARTICIPANTS: Randomized, nonblinded clinical trial of blood donors stratified by ferritin level, sex, and age conducted in 4 regional blood centers in the United States in 2012. Included were 215 eligible participants aged 18 to 79 years who had not donated whole blood or red blood cells within 4 months. INTERVENTIONS: One tablet of ferrous gluconate (37.5 mg of elemental iron) daily or no iron for 24 weeks (168 days) after donating a unit of whole blood (500 mL). MAIN OUTCOMES AND MEASURES: Time to recovery of 80% of the postdonation decrease in hemoglobin and recovery of ferritin level to baseline as a measure of iron stores. RESULTS: The mean baseline hemoglobin levels were comparable in the iron and no-iron groups and declined from a mean (SD) of 13.4 (1.1) g/dL to 12.0 (1.2) g/dL after donation in the low-ferritin group and from 14.2 (1.1) g/dL to 12.9 (1.2) g/dL in the higher-ferritin group. Compared with participants who did not receive iron supplementation, those who received iron supplementation had shortened time to 80% hemoglobin recovery in both the low-ferritin (mean, 32 days, interquartile range [IQR], 30-34, vs 158 days, IQR, 126->168) and higher-ferritin groups (31 days, IQR, 29-33, vs 78 days, IQR, 66-95). Median time to recovery to baseline ferritin levels in the low-ferritin group taking iron was 21 days (IQR, 12-84). For participants not taking iron, recovery to baseline was longer than 168 days (IQR, 128->168). Median time to recovery to baseline in the higher-ferritin group taking iron was 107 days (IQR, 75-141), and for participants not taking iron, recovery to baseline was longer than 168 days (IQR, >168->168). Recovery of iron stores in all participants who received supplements took a median of 76 days (IQR, 20-126); for participants not taking iron, median recovery time was longer than 168 days (IQR, 147->168 days; P < .001). Without iron supplements, 67% of participants did not recover iron stores by 168 days. CONCLUSIONS AND RELEVANCE: Among blood donors with normal hemoglobin levels, low-dose iron supplementation, compared with no supplementation, reduced time to 80% recovery of the postdonation decrease in hemoglobin concentration in donors with low ferritin (≤26 ng/mL) or higher ferritin (>26 ng/mL). TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01555060.
Authors: Ritchard G Cable; Whitney R Steele; Russell S Melmed; Bryce Johnson; Alan E Mast; Patricia M Carey; Joseph E Kiss; Steven H Kleinman; David J Wright Journal: Transfusion Date: 2011-10-20 Impact factor: 3.157
Authors: Ritchard G Cable; Simone A Glynn; Joseph E Kiss; Alan E Mast; Whitney R Steele; Edward L Murphy; David J Wright; Ronald A Sacher; Jerry L Gottschall; Leslie H Tobler; Toby L Simon Journal: Transfusion Date: 2011-10-24 Impact factor: 3.157
Authors: Alan E Mast; Karen S Schlumpf; David J Wright; Brian Custer; Bryan Spencer; Edward L Murphy; Toby L Simon Journal: Transfusion Date: 2010-04-15 Impact factor: 3.157
Authors: A Mireille Baart; Paulus A H van Noord; Yvonne Vergouwe; Karel G M Moons; Dorine W Swinkels; Erwin T Wiegerinck; Wim L A M de Kort; Femke Atsma Journal: Transfusion Date: 2012-11-26 Impact factor: 3.157
Authors: Martin Falkingham; Asmaa Abdelhamid; Peter Curtis; Susan Fairweather-Tait; Louise Dye; Lee Hooper Journal: Nutr J Date: 2010-01-25 Impact factor: 3.271
Authors: Graham A Smith; Sheila A Fisher; Carolyn Doree; Emanuele Di Angelantonio; David J Roberts Journal: Cochrane Database Syst Rev Date: 2014-07-03
Authors: Alan E Mast; John C Langer; Yuelong Guo; Walter Bialkowski; Bryan R Spencer; Tzong-Hae Lee; Joseph Kiss; Ritchard G Cable; Donald Brambilla; Michael P Busch; Grier P Page Journal: Transfusion Date: 2020-03-12 Impact factor: 3.157
Authors: Ritchard G Cable; Rebecca J Birch; Bryan R Spencer; David J Wright; Walter Bialkowski; Joseph E Kiss; Jorge Rios; Barbara J Bryant; Alan E Mast Journal: Transfusion Date: 2017-07-13 Impact factor: 3.157
Authors: Tamir Kanias; Mars Stone; Grier P Page; Yuelong Guo; Stacy M Endres-Dighe; Marion C Lanteri; Bryan R Spencer; Ritchard G Cable; Darrell J Triulzi; Joseph E Kiss; Edward L Murphy; Steve Kleinman; Mark T Gladwin; Michael P Busch; Alan E Mast Journal: Transfusion Date: 2018-11-26 Impact factor: 3.157
Authors: Tomislav Vuk; Karin Magnussen; Wim De Kort; Gilles Folléa; Giancarlo M Liumbruno; Harald Schennach; Giovani Vandewalle; Veerle Compernolle; Natalia Masharova; Georgia Karakatsiani; Isabella Argyrou; Vít Řeháček; Gulara Khanirzajeva; Johanna Castrén; Bruno Danic; Rachid Djoudi; Geneviève Woimant; Markus M Mueller; Constantina Politis; Stefania Vaglio; Anita Daugavvanaga; Edita Vilutytė; Jean-Claude Faber; Denise Borg-Aquilina; Peter Van Den Burg; Arlinke Bokhorst; Ryszard Pogłód; Jolanta Antoniewicz-Papis; Mario Muon; Olivia L Burta; Jana Rosochová; Polonca Mali; Miguel A Vesga; Karin Schneider; Rut Norda; Nicky Anderson Journal: Blood Transfus Date: 2016-09-07 Impact factor: 3.443
Authors: Alan E Mast; Aniko Szabo; Mars Stone; Ritchard G Cable; Bryan R Spencer; Joseph E Kiss Journal: Am J Hematol Date: 2020-04-15 Impact factor: 10.047